Multifactorial intervention in Type 2 XXXX : the promise of incretin-based therapies.

@entity1 @entity5735 @entity6 @entity1560 @entity165 @entity412 @entity551 @entity65 @entity5445
@entity6 is increasing in prevalence at alarming rates. Concurrent with its expanding prevalence is the increase in the related risk of morbidity and mortality. Because @entity6 @entity1 are prone to @entity65 , treatment strategies should address the cardiovascular risk factors, including blood pressure, lipids, and body weight, in addition to the glycemic aspects of the disease. Newer agents, such as @entity5445 ( @entity5445 ) analogs and @entity5735 ( @entity5735 ) inhibitors, have varying degrees of evidence to support their effects on body weight, blood pressure, and lipid levels, beyond glycated hemoglobin reduction. While @entity5445 agonists produce a weight loss, the @entity5735 inhibitors, conversely, appear to have a weight-neutral effect. Substantial evidence demonstrates that both medications produce modest @entity551 and, in some cases, diastolic blood pressure, and reduce several markers of cardiovascular risk, including C-reactive protein. Moreover, @entity5445 influences endothelial function. The effect of the incretin hormones on serum lipids are either neutral or beneficial, with small, non-significant decreases in LDL @entity165 , increases in HDL @entity165 , and occasionally significant decreases in fasting @entity412 levels. Also, they have positive effects on @entity1560 . Although @entity5445 agonists and @entity5735 inhibitors are at present not appropriate for primary treatment of cardiovascular risks factors, the reduction of these parameters is evidently beneficial.
